Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06864169 · ClinicalTrials.gov registry record · Phase 2

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

A Phase 2 study of Gastrointestinal Cancer, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 2
Development phase
160
Enrollment target
20
Study locations

NCT06864169 is a Phase 2 study of Gastrointestinal Cancer that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 160 participants, below the 230-participant average among 48 other Gastrointestinal Cancer trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06864169, a Phase 2 study of Gastrointestinal Cancer, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
160 participants
Enrollment target
20
Study locations

Study Summary

Researchers are looking for new ways to treat certain types of advanced gastrointestinal (GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of medicine called an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goal of this study is to learn if the cancer responds to treatment (gets smaller or goes away).

Conditions Studied

Gastrointestinal Cancer

Interventions

  • BIOLOGICAL Raludotatug Deruxtecan (R-DXd)

Study Locations (20)

Region M. de Santiago

  • FALP ( Site 0062) - Santiago
  • Centro de Estudios Clínicos SAGA ( Site 0064) - Santiago
  • Clínica UC San Carlos de Apoquindo ( Site 0066) - Santiago
  • Bradfordhill ( Site 0069) - Santiago

Ontario

  • Sunnybrook Research Institute ( Site 0044) - Toronto
  • Princess Margaret Cancer Centre ( Site 0041) - Toronto

Connecticut

  • Yale New Haven Hospital ( Site 0375) - New Haven

District of Columbia

  • Sibley Memorial Hospital ( Site 0372) - Washington D.C.

Florida

  • Mt Sinai Comprehensive Cancer Center ( Site 0345) - Miami Beach

Montana

  • St. Vincent Healthcare Frontier Cancer Center ( Site 0347) - Billings

New Jersey

  • Morristown Medical Center ( Site 0349) - Morristown

Ohio

  • University Hospitals Cleveland Medical Center ( Site 0369) - Cleveland

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2025-04-01
Est. Completion 2029-01-04
Phase Phase 2

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06864169

The ClinicalTrials.gov registry entry for NCT06864169 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 230-participant average among 48 other Gastrointestinal Cancer trials with a reported enrollment target (30% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastrointestinal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Raludotatug Deruxtecan (R-DXd) is the first listed.

NCT06864169 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Region M. de Santiago, Ontario, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06864169 about?

NCT06864169 is a clinical study titled "A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)". Researchers are looking for new ways to treat certain types of advanced gastrointestinal (GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of medicine called an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and d...

What is the current status of trial NCT06864169?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-04-01. Estimated completion is 2029-01-04.

What conditions does trial NCT06864169 study?

This clinical trial studies the following conditions: Gastrointestinal Cancer.

What interventions are being tested in trial NCT06864169?

The interventions under investigation include: Raludotatug Deruxtecan (R-DXd) (BIOLOGICAL).

Who is sponsoring clinical trial NCT06864169?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06864169 being conducted?

This trial has 20 study locations across Connecticut, District of Columbia, Florida, Montana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastrointestinal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastrointestinal Cancer

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.